Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
-
+
JCSE 01.01 - Breakfast and Poster Viewing
07:30 - 07:55
- Abstract
No abstract available for this presentation
-
+
JCSE 01.02 - Welcome and Introduction
07:55 - 08:00
- Abstract
No abstract available for this presentation
-
+
JCSE 01.03 - The Science of Immunotherapy
08:00 - 08:20 | Presenter: Roy S. Herbst
- Abstract
No abstract available for this presentation
-
+
JCSE 01.05 - PD-1+CD8+ T and iNKT Cell Based Immunotherapy on Lung Cancer
08:20 - 08:40 | Presenter: Jianqing Xu
- Abstract
No abstract available for this presentation
-
+
JCSE 01.06 - ctDNA Based Tumor Mutation Burden Evaluation for Predicting Immunotherapy Effect
08:40 - 09:00 | Presenter: Jie Hu
- Abstract
No abstract available for this presentation
-
+
JCSE 01.07 - Ongoing Trials in China on Checkpoint Inhibitors and Other Immunotherapies
09:00 - 09:20 | Presenter: Qing Zhou
- Abstract
Loading... -
+
JCSE 01.08 - Coffee Break and Poster Viewing
09:20 - 09:45
- Abstract
No abstract available for this presentation
-
+
JCSE 01.09 - Therapeutic Practices in Europe for Immunotherapy, including Biomarkers
09:45 - 10:05 | Presenter: Solange Peters
- Abstract
No abstract available for this presentation
-
+
JCSE 01.10 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
10:05 - 10:20 | Presenter: Songtao Xu | Author(s): W. Zhong, Y. Zhang, W. Mao, L. Wu, Y. Shen, Y. Liu, C. Chen, Ying Cheng, L. Xu, J. Wang, K. Fei, X. Li, J. Li, C. Huang, Z. Liu, S. Xu, K. Chen, S. Xu, L. Liu, P. Yu, B. Wang, H. Ma, H. Yan, X. Yang, Yi-Long Wu, Q. Wang
- Abstract
Loading... -
+
JCSE 01.11 - A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China
10:20 - 10:35 | Presenter: Ying Cheng | Author(s): Y. Wang, J. Zhao, Y. Liu, H. Gao, K. Ma, S. Zhang, H. Xin, J. Liu, H. Chengbo, Z. Zhu, Y. Wang, J. Chen, F. Wen, J. Li, Z. Jie, Z. Zheng, Z. Dai, H. Piao, X. Li, Y. Li, M. Zhong, R. Ma, Y. Zhuang, Y. Xu, Z. Qu, H. Yang, C. Pan, F. Yang, D. Zhang, B. Li
- Abstract
Loading... -
+
- Abstract
Loading... -
+
JCSE 01.13 - Discussant Oral Abstracts - JCSE 01.10, JCSE 01.11, JCSE 01.12
10:50 - 11:10 | Presenter: Joel W. Neal
- Abstract
No abstract available for this presentation
-
+
JCSE 01.14 - Discussant Poster Abstracts
11:10 - 11:30 | Presenter: Bob T. Li, Jonathan W Riess
- Abstract
No abstract available for this presentation
-
+
- Abstract
Loading... -
+
- Abstract
Loading... -
+
- Abstract
Loading... -
+
- Abstract
Loading... -
+
JCSE 01.21 - Combination of Biomarker and Clinicopathologic Characters May Circle out Beneficiaries through Second-Line Immunotherapy: A Meta Analyse
11:30 - 11:30 | Presenter: Si-Yang Liu | Author(s): Z. Dong, C. Zhang, W. Zhong, Yi-Long Wu
- Abstract
Loading... -
+
JCSE 01.23 - The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGFR-TKI Resistance: A Preliminary Study
11:30 - 11:30 | Presenter: Lucheng Zhu | Author(s): S. Zhang, B. Xia, X. Chen, S. Ma
- Abstract
Loading... -
+
JCSE 01.24 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
11:30 - 11:30 | Presenter: Tony SK Mok | Author(s): Shun Lu, Ying Cheng, Jie Wang, Y. Wang, T. Wang, T. Yung, X. Su, F. Sun, F. Sun, L.T. Wang, Yi-Long Wu
- Abstract
Loading... -
+
JCSE 01.25 - Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC
11:30 - 11:30 | Presenter: Xu-Chao Zhang | Author(s): Z. Liang, Y. Chen, H. Zhang, W. Gang, Y. Lu, Z. Liang, Ying Cheng, Y. Hu, Jie Wang, J. Ying, W. Liu, Yi-Long Wu
- Abstract
Loading... -
+
JCSE 01.26 - Circulating Cell-Free DNA of Cerebrospinal Fluid May Function as Liquid Biopsy for Leptomeningeal Metastases of ALK Rearrangement NSCLC
11:30 - 11:30 | Presenter: Yangsi Li | Author(s): B. Jiang, Jin -Ji Yang, X. Zhang, Z. Zhang, Qing Zhou, H. Tu, Z. Wang, H. Chen, C. Xu, B. Wang, Yi-Long Wu
- Abstract
Loading... -
+
JCSE 01.27 - Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
11:30 - 11:30 | Presenter: Tony SK Mok | Author(s): Solange Peters, D. Ross Camidge, Shirish M Gadgeel, S.I. Ou, D. Kim, Rafal Dziadziuszko, F. De Marinis, R. Sangha, A. Zeaiter, J. Noe, E. Nueesch, T. Liu, I. Loftin, C. Williams, Alice Shaw
- Abstract
Loading... -
+
JCSE 01.28 - NGS Sequencing Based Liquid / Tissue Biopsy Identified Coexistence of HER2 Amplification and Mutation in Advanced NSCLC Patients
11:30 - 11:30 | Presenter: Rongrong Chen | Author(s): J. Zhao, G. Lin, L. Liu, L. Chen, X. Hu, X. Ai, Z. Fan, C. Xu, W. Wang, W. Zhuang, M. Fang, Y. Zhu, G. Chen, Y. Guan, L. Yang, X. Xia, X. Yi
- Abstract
Loading... -
+
JCSE 01.29 - Closing Remarks
11:30 - 11:30
- Abstract
No abstract available for this presentation
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-009 - Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Jin Kang | Author(s): H. Chen, X. Zhang, Qing Zhou, H. Tu, Yi-Long Wu, Jin -Ji Yang
- Abstract
Loading... -
+
P1.01-010 - Circulating Cell-Free DNA of Cerebrospinal Fluid May Function as Liquid Biopsy for Leptomeningeal Metastases of ALK Rearrangement NSCLC
09:30 - 09:30 | Presenter: Yangsi Li | Author(s): Benyuan Jiang, Jin -Ji Yang, X. Zhang, Z. Zhang, W. Zhong, Qing Zhou, H. Tu, Z. Wang, H. Chen, C. Xu, B. Wang, Yi-Long Wu
- Abstract
Loading... -
+
P1.01-018 - Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression
09:30 - 09:30 | Presenter: Anna Li | Author(s): Jin -Ji Yang, X.C. Zhang, J. Su, Qing Zhou, H. Chen, Z. Xie, H. Tu, W. Zhong, Z. Wang, C. Xu, Z. Chen, H. Yan, Yi-Long Wu
- Abstract
Loading... -
+
P1.01-027 - Combination of Biomarker and Clinicopathologic Characters May Circle out Beneficiaries through Second-Line Immunotherapy: A Meta Analyse
09:30 - 09:30 | Presenter: Si-Yang Liu | Author(s): Z. Dong, C. Zhang, W. Zhong, Yi-Long Wu
- Abstract
Loading... -
+
P1.01-032 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
09:30 - 09:30 | Presenter: Tony SK Mok | Author(s): Shun Lu, Ying Cheng, Jie Wang, Y. Wang, T. Wang, T. Yung, X. Su, F. Sun, L.T. Wang, Yi-Long Wu
- Abstract
Loading...
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P1.04-010 - CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
09:30 - 09:30 | Presenter: Shun Lu | Author(s): Li Zhang, Ying Cheng, Jie Wang, C. Wang, M. Wang, X. Li, Q. Wu, Yi-Long Wu
- Abstract
Loading...
-
+
P1.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P1.07-042 - PD-L1 and CD8 Expression in EGFR-Mutant or ALK-Rearranged Patients with Lung Cancer
09:30 - 09:30 | Presenter: Yi-Long Wu | Author(s): S. Liu, Z. Dong, S. Wu, Z. Xie, J. Su, Jin -Ji Yang, X. Yang
- Abstract
Loading...
-
+
P1.13 - Radiology/Staging/Screening
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Radiology/Staging/Screening
-
+
P1.13-001 - T1 Tumor(≪3cm) with Visceral Pleural Invasion Should Be Classified as T2a in the 8th TNM Classification for Lung Cancer
09:30 - 09:30 | Presenter: Jia-Tao Zhang | Author(s): Wen -Feng Li, J. Lin, Si-Yang Liu, Jin -Ji Yang, X. Yang, Yi-Long Wu, W. Zhong
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.01 - First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
15:45 - 15:55 | Presenter: Yi-Long Wu | Author(s): Ying Cheng, X. Zhou, K.H. Lee, Kazuhiko Nakagawa, Seiji Niho, F. Tsuji, Rafael Rosell, J. Corral, M.R. Migliorino, A. Pluzanski, R. Linke, E.I. Sbar, T. Wang, H. Zhang, Tony SK Mok
- Abstract
Loading...
-
+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P2.03-047 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
09:30 - 09:30 | Presenter: Songtao Xu | Author(s): W. Zhong, Y. Zhang, W. Mao, L. Wu, Y. Shen, Y. Liu, C. Chen, Ying Cheng, L. Xu, J. Wang, K. Fei, X. Li, J. Li, C. Huang, Z. Liu, S. Xu, K. Chen, S. Xu, L. Liu, P. Yu, B. Wang, H. Ma, H. Yan, X. Yang, Yi-Long Wu, Q. Wang
- Abstract
Loading... -
+
P2.03-054 - EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities
09:30 - 09:30 | Presenter: Shan Su | Author(s): Z.Y. Dong, Jin -Ji Yang, X. Zhang, Z. Xie, J. Su, Z. Chen, Yi-Long Wu
- Abstract
Loading...
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P2.04-006 - ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection
09:30 - 09:30 | Presenter: Roy S. Herbst | Author(s): Yi-Long Wu, H. Mann, Y. Rukazenkov, M. Marotti, M. Tsuboi
- Abstract
Loading... -
+
P2.04-012 - First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study
09:30 - 09:30 | Presenter: Yi-Long Wu | Author(s): Tony SK Mok, Martin Reck, Heather A Wakelee, C. Liang, F. Tan, K. Harrow, V. Oertel, G. Dukart, L. Ding, L. Horn
- Abstract
Loading...
-
+
P2.08 - Locally Advanced Nsclc
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Locally Advanced NSCLC
-
+
P2.08-002 - A Nomogram for Predicting Underlying Beneficiaries for Resectable IIIA/N2 NSCLC Patients
09:30 - 09:30 | Presenter: Chao Zhang | Author(s): Y. Chen, H. Zhai, X. Yang, Yi-Long Wu, W. Zhong
- Abstract
Loading...
-
+
MA 11 - Emerging Diagnostic/Biomarkers in NSCLC
- 11:00 - 12:30
- 10/17/2017
- Location: Room 313 + 314
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:M.I. Abdul Wahid, Martin Reck
-
+
MA 11.03 - Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
11:10 - 11:15 | Presenter: Jie Wang | Author(s): Ying Cheng, Yi-Long Wu, T. An, H. Gao, K. Wang, Qing Zhou, Y. Hu, Yong Song, C. Ding, F. Peng, L. Liang, Y. Hu, C. Huang, Caicun Zhou, Y. Shi, Li Zhang, X. Ye, Y. Sun
- Abstract
Loading...